Mark Altmeyer, Arvelle

In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

With a team of Ax­o­vant vet­er­ans lead­ing the way, CNS start­up Arvelle Ther­a­peu­tics is near­ing ap­proval for li­censed epilep­sy med cenoba­mate in the EU af­ter snag­ging an FDA ap­proval in late 2019. Look­ing to take its first med to mar­ket, Arvelle has agreed to hand the reins to Italy’s An­geli­ni Phar­ma in the first big bio­phar­ma buy­out of 2021.

An­geli­ni will pay $610 mil­lion post-ap­proval with $350 mil­lion in sales mile­stones to ac­quire Switzer­land’s Arvelle, a team helmed by three vet­er­ans from the Vivek Ra­maswamy out­fit that ex­pects an EU nod for cenoba­mate this year, the com­pa­nies said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.